VIR
Vir Biotechnology, Inc.
$8.45
-2.31%
$1.4B
No data for this timeframe.
Vol
Market Cap$1.4B
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (93%)
Inst. Holders8 funds
Inst. Value$129.8M
Inst. Activity2 buys / 1 sells
Insider Activity0B / 20S
Insider Net $-$2.2M
SEC Reports12
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·Inc. DE·CIK 0001706431·Prev Close $8.65
Recent Activity
Jun 3, 2026
short_volume
Short Volume: VIR — 65.0% short (0.7M / 1.1M)
Short: 687,834 | Exempt: 94 | TRF Vol: 1,058,683 | Short Ratio: 65.0% | Off-exchange volume (dark po
Jun 2, 2026
SEC
Two insiders at Vir Biotechnology sold a combined $34K in open-market sales on June 1, 2026, following a wave of non-cas
CLUSTER — Impact 2/10
Jun 1, 2026
Insider
Sabatini Brent sold 379 shares
SVP, Chief Accounting Officer @ $9.45 ($3.6K)
Jun 1, 2026
Insider
Napolitano Janet sold 3,200 shares
Director @ $9.45 ($30.2K)
May 28, 2026
SEC
Vir Biotechnology filed an 8-K reporting the departure of board member and Audit Committee Chair Saira Ramasastry due to
8-K — Impact 2/10
May 27, 2026
Insider
Napolitano Janet sold 8,000 shares
Director @ $0.00 ($0.00)
Apr 16, 2026
SEC
Vir Biotechnology filed a definitive proxy statement (DEFA14A) following the recent departure of its Chief Medical Offic
DEFA14A — Impact 3/10
Inst.
BANK OF AMERICA CORP — DOUBLED
930,908 shares ($5.6M)
Price Targets
$21.11
+148.1% upside
Strong Buy
Current $8.51
Low $16.00
Median $21.00
High $30.00
9 analysts
$16.00
$30.00
Analyst Ratings
4Strong Buy
9Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jun 3, 2026 | Leerink Partners | MAINTAIN | Outperform → Outperform |
| Mar 4, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| Feb 25, 2026 | Barclays | MAINTAIN | Overweight → Overweight |
| Feb 24, 2026 | Morgan Stanley | MAINTAIN | Overweight → Overweight |
| Feb 24, 2026 | Evercore ISI Group | MAINTAIN | Outperform → Outperform |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $0.90 ▲ +6.7% | $0.47 — $1.45 | 212% YoY | 5 |
| Next Q | $-0.81 ▼ -3.3% | $-1.02 — $-0.65 | 31% YoY | 5 |
| Current FY | $-1.37 ▲ +0.8% | $-1.74 — $-1.20 | 57% YoY | 5 |
| Next FY | $-2.32 ▼ -3.2% | $-2.99 — $-1.87 | -69% YoY | 4 |
Latest Reports
NEUTRAL
CLUSTER
2/10
Two insiders at Vir Biotechnology sold a combined $34K in open-market sales on June 1, 2026, following a wave of non-cas
Jun 2, 2026
NEUTRAL
8-K
2/10
Vir Biotechnology filed an 8-K reporting the departure of board member and Audit Committee Chair Saira Ramasastry due to
May 28, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $75.7M | — |
| FMR LLC | $19.0M | ADD |
| MORGAN STANLEY | $16.2M | ADD |
| BANK OF AMERICA CORP | $5.6M | DOUBLED |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $5.5M | NEW |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 1, 2026 | Sabatini Brent | SELL | $3.6K |
| Jun 1, 2026 | Napolitano Janet | SELL | $30.2K |
| May 27, 2026 | Napolitano Janet | A | $0.00 |
| May 27, 2026 | BISCHOFBERGER NORBERT | A | $0.00 |
| May 27, 2026 | BISCHOFBERGER NORBERT | A | $0.00 |
8 institutional holders with $129.8M total value (21,531,330 shares) as of 2025-Q4. Top holders: VANGUARD, FMR, MORGAN. Net buying activity: 2 institutions added/increased vs 1 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 12,548,944 | $75.7M | 58.3% | — |
| 2 | FMR LLC | 3,158,416 | $19.0M | 14.7% | ADD +60.6% |
| 3 | MORGAN STANLEY | 2,679,145 | $16.2M | 12.4% | ADD +64.6% |
| 4 | BANK OF AMERICA CORP /DE/ | 930,908 | $5.6M | 4.3% | DOUBLED +132.2% |
| 5 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 904,480 | $5.5M | 4.2% | NEW |
| 6 | RENAISSANCE TECHNOLOGIES LLC | 614,464 | $3.7M | 2.9% | TRIM -47.4% |
| 7 | TWO SIGMA INVESTMENTS, LP | 589,561 | $3.6M | 2.7% | ADD +75.7% |
| 8 | WELLS FARGO & COMPANY/MN | 105,412 | $635.6K | 0.5% | ADD +39.7% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| BANK OF AMERICA CORP /DE/ | DOUBLED | 400,983 | 930,908 | +132.2% | $5.6M | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 1,167,100 | 614,464 | -47.4% | $3.7M | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 75,445 | 105,412 | +39.7% | $635.6K | 2025-Q4 |
| MORGAN STANLEY | ADD | 1,633,690 | 2,689,118 | +64.6% | $15.4M | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | ADD | 369,615 | 649,300 | +75.7% | $3.7M | 2025-Q3 |
| UBS Group AG | TRIM | 315,167 | 214,762 | -31.9% | $1.2M | 2025-Q3 |
| FMR LLC | ADD | 2,216,434 | 3,558,655 | +60.6% | $17.9M | 2025-Q2 |
| TWO SIGMA INVESTMENTS, LP | ADD | 272,535 | 369,615 | +35.6% | $1.9M | 2025-Q2 |
| UBS Group AG | TRIM | 477,396 | 315,167 | -34.0% | $1.6M | 2025-Q2 |
| FMR LLC | DOUBLED | 7,116 | 2,216,434 | +31047.2% | $14.4M | 2025-Q1 |
| CITADEL ADVISORS LLC | DOUBLED | 321,064 | 1,677,028 | +422.3% | $10.9M | 2025-Q1 |
| MORGAN STANLEY | ADD | 1,123,806 | 1,424,345 | +26.7% | $9.2M | 2025-Q1 |
| UBS Group AG | ADD | 240,113 | 477,396 | +98.8% | $3.1M | 2025-Q1 |
| UBS Group AG | TRIM | 383,188 | 240,113 | -37.3% | $1.8M | 2024-Q4 |
| WELLS FARGO & COMPANY/MN | NEAR_EXIT | 251,757 | 52,661 | -79.1% | $386.5K | 2024-Q4 |
| MORGAN STANLEY | TRIM | 2,123,212 | 1,236,919 | -41.7% | $9.3M | 2024-Q3 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 1,134,276 | — | $8.5M | 2024-Q3 |
12 unique insiders with 20 transactions. Net insider value: -$2.2M ($0.00 bought, $2.2M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 1, 2026 | Sabatini Brent | SVP, Chief Accounting Officer | SELL | 379 | $9.45 | $3.6K |
| Jun 1, 2026 | Napolitano Janet | Director | SELL | 3,200 | $9.45 | $30.2K |
| May 27, 2026 | Napolitano Janet | Director | A | 8,000 | $0.00 | $0.00 |
| May 27, 2026 | BISCHOFBERGER NORBERT W | Director | A | 8,000 | $0.00 | $0.00 |
| May 27, 2026 | BISCHOFBERGER NORBERT W | Director | A | 16,000 | $0.00 | $0.00 |
| May 27, 2026 | Farid Ramy | Director | A | 8,000 | $0.00 | $0.00 |
| May 27, 2026 | Farid Ramy | Director | A | 16,000 | $0.00 | $0.00 |
| May 27, 2026 | Hatfield Jeffrey S. | Director | A | 8,000 | $0.00 | $0.00 |
| May 27, 2026 | Hatfield Jeffrey S. | Director | A | 16,000 | $0.00 | $0.00 |
| May 27, 2026 | MORE ROBERT J | Director | A | 8,000 | $0.00 | $0.00 |
| May 27, 2026 | MORE ROBERT J | Director | A | 16,000 | $0.00 | $0.00 |
| May 27, 2026 | Napolitano Janet | Director | A | 16,000 | $0.00 | $0.00 |
| May 27, 2026 | Sigal Charles Elliott | Director | A | 8,000 | $0.00 | $0.00 |
| May 27, 2026 | Sigal Charles Elliott | Director | A | 16,000 | $0.00 | $0.00 |
| May 1, 2026 | SATO VICKI L | Director | SELL | 22,000 | $10.05 | $221.0K |
| Apr 29, 2026 | De Backer Marianne | President and CEO | J | 233,532 | $0.00 | $0.00 |
| Apr 6, 2026 | De Backer Marianne | President and CEO | SELL | 72,559 | $9.16 | $664.4K |
| Apr 1, 2026 | SATO VICKI L | Director | SELL | 22,000 | $9.07 | $199.6K |
| Mar 23, 2026 | Sabatini Brent | SVP, Chief Accounting Officer | SELL | 7,711 | $9.12 | $70.3K |
| Mar 20, 2026 | O'Byrne Jason | EVP & Chief Financial Officer | J | 2,500 | $0.00 | $0.00 |
| Mar 2, 2026 | SATO VICKI L | Director | SELL | 21,800 | $9.50 | $207.2K |
| Feb 25, 2026 | Eisner Mark | EVP and Chief Medical Officer | SELL | 1,889 | $9.82 | $18.5K |
| Feb 25, 2026 | de Verneuil Vanina | EVP, General Counsel, Corp Sec | SELL | 13,700 | $9.82 | $134.5K |
| Feb 24, 2026 | SATO VICKI L | Director | M | 42,377 | $0.00 | $0.00 |
| Feb 24, 2026 | Sabatini Brent | SVP, Chief Accounting Officer | SELL | 1,430 | $9.53 | $13.6K |
| Feb 24, 2026 | de Verneuil Vanina | EVP, General Counsel, Corp Sec | SELL | 3,117 | $9.53 | $29.7K |
| Feb 24, 2026 | O'Byrne Jason | EVP & Chief Financial Officer | SELL | 1,634 | $9.53 | $15.6K |
| Feb 24, 2026 | SATO VICKI L | Director | M | 42,377 | $1.49 | $62.9K |
| Feb 24, 2026 | Eisner Mark | EVP and Chief Medical Officer | SELL | 1,616 | $9.53 | $15.4K |
| Feb 24, 2026 | De Backer Marianne | Chief Executive Officer | SELL | 14,762 | $9.53 | $140.7K |
| Feb 23, 2026 | de Verneuil Vanina | EVP, General Counsel, Corp Sec | SELL | 4,445 | $7.45 | $33.1K |
| Feb 23, 2026 | De Backer Marianne | Chief Executive Officer | SELL | 19,039 | $7.45 | $141.9K |
| Feb 23, 2026 | Sabatini Brent | SVP, Chief Accounting Officer | SELL | 1,829 | $7.45 | $13.6K |
| Feb 23, 2026 | O'Byrne Jason | EVP & Chief Financial Officer | SELL | 2,089 | $7.45 | $15.6K |
| Feb 23, 2026 | Eisner Mark | EVP and Chief Medical Officer | SELL | 2,089 | $7.45 | $15.6K |
| Feb 22, 2026 | Sabatini Brent | SVP, Chief Accounting Officer | A | 25,000 | $0.00 | $0.00 |
| Feb 22, 2026 | Sabatini Brent | SVP, Chief Accounting Officer | A | 50,000 | $0.00 | $0.00 |
| Feb 22, 2026 | O'Byrne Jason | EVP & Chief Financial Officer | A | 55,000 | $0.00 | $0.00 |
| Feb 22, 2026 | Eisner Mark | EVP and Chief Medical Officer | A | 110,000 | $0.00 | $0.00 |
| Feb 22, 2026 | de Verneuil Vanina | EVP, General Counsel, Corp Sec | A | 55,000 | $0.00 | $0.00 |
| Feb 22, 2026 | de Verneuil Vanina | EVP, General Counsel, Corp Sec | A | 110,000 | $0.00 | $0.00 |
| Feb 22, 2026 | Eisner Mark | EVP and Chief Medical Officer | A | 55,000 | $0.00 | $0.00 |
| Feb 22, 2026 | O'Byrne Jason | EVP & Chief Financial Officer | A | 110,000 | $0.00 | $0.00 |
| Feb 22, 2026 | De Backer Marianne | Chief Executive Officer | A | 285,000 | $0.00 | $0.00 |
| Feb 22, 2026 | De Backer Marianne | Chief Executive Officer | A | 570,000 | $0.00 | $0.00 |
| Feb 2, 2026 | SATO VICKI L | Director | SELL | 22,000 | $7.71 | $169.7K |
12 SEC filing reports analyzed. Sentiment: 0 bullish, 4 bearish, 0 mixed, 8 neutral. Avg impact: 3.9/10.
NEUTRAL
CLUSTER
2/10
Two insiders at Vir Biotechnology sold a combined $34K in open-market sales on June 1, 2026, followi
Jun 2, 2026
NEUTRAL
8-K
2/10
Vir Biotechnology filed an 8-K reporting the departure of board member and Audit Committee Chair Sai
May 28, 2026
NEUTRAL
DEFA14A
3/10
Vir Biotechnology filed a definitive proxy statement (DEFA14A) following the recent departure of its
Apr 16, 2026
NEUTRAL
8-K
3/10
Vir Biotechnology's Chief Medical Officer, Mark Eisner, is stepping down effective April 24, 2026, a
Apr 10, 2026
BEARISH
CLUSTER
6/10
Vir Biotechnology's CEO and a board director collectively sold $864K worth of shares in the past wee
Apr 7, 2026
NEUTRAL
8-K
3/10
Vir Biotechnology appointed CEO Marianne De Backer to the additional role of President. This is an i
Mar 4, 2026
BEARISH
CLUSTER
5/10
Three corporate insiders at Vir Biotechnology sold shares in the past seven days, including two exec
Mar 3, 2026
BEARISH
CLUSTER
5/10
Multiple C-suite executives at Vir Biotechnology, including the CEO, CFO, and General Counsel, condu
Feb 26, 2026
NEUTRAL
CLUSTER
4/10
Multiple top executives at Vir Biotechnology, including the CEO, CFO, and CMO, sold shares worth ove
Feb 25, 2026
NEUTRAL
CLUSTER
4/10
Multiple top executives at Vir Biotechnology, including the CEO, CFO, and Chief Medical Officer, sol
Feb 25, 2026
BEARISH
CLUSTER
6/10
Multiple C-suite executives at Vir Biotechnology, including the CEO, CMO, and General Counsel, sold
Feb 25, 2026
NEUTRAL
CLUSTER
4/10
CEO Marianne De Backer and EVP Vanina de Verneuil sold significant shares in Vir Biotechnology, tota
Feb 25, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Strong Buy (93% buy). Based on 14 analysts: 4 strong buy, 9 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$21.11 mean target
+148.1% upside
Strong Buy (1.30)
$16.00 Low
$30.00 High
| Metric | Value |
|---|---|
| Current Price | $8.51 |
| Target Low | $16.00 |
| Target Mean | $21.11 |
| Target Median | $21.00 |
| Target High | $30.00 |
| # Analysts | 9 |
| Recommendation | Strong Buy (1.30) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$0.90 | $0.47 | $1.45 | 211.9% | +6.7% | — | $0.2B | 18233.6% | 5 |
| Next Q 2026-09-30 |
$-0.81 | $-1.02 | $-0.65 | 31.1% | -3.3% | 2↑ 0↓ | $0.0B | 33.3% | 5 |
| Current FY 2026-12-31 |
$-1.37 | $-1.74 | $-1.20 | 56.5% | +0.8% | 2↑ 2↓ | $0.2B | 263.8% | 5 |
| Next FY 2027-12-31 |
$-2.32 | $-2.99 | $-1.87 | -69.2% | -3.2% | 2↑ 2↓ | $0.1B | -54.7% | 4 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $0.895 | |
| 7d ago | $0.895 | |
| 30d ago | $0.839 | +0.056 |
| 60d ago | $-0.633 | +1.529 |
| 90d ago | $-0.633 | +1.529 |
6 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jun 3, 2026 | Leerink Partners | MAINTAIN | Outperform | Outperform |
| Mar 4, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Feb 25, 2026 | Barclays | MAINTAIN | Overweight | Overweight |
| Feb 24, 2026 | Morgan Stanley | MAINTAIN | Overweight | Overweight |
| Feb 24, 2026 | Evercore ISI Group | MAINTAIN | Outperform | Outperform |
| Feb 24, 2026 | Needham | MAINTAIN | Buy | Buy |
| Feb 9, 2026 | Needham | REITERATE | Buy | Buy |
| Dec 30, 2025 | HC Wainwright & Co. | REITERATE | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 4 | 9 | 1 | 0 | 0 | 93% | |
| May 1, 2026 | 4 | 9 | 1 | 0 | 0 | 93% | |
| Apr 1, 2026 | 4 | 9 | 1 | 0 | 0 | 93% | |
| Mar 1, 2026 | 3 | 10 | 1 | 0 | 0 | 93% | |
| Feb 1, 2026 | 3 | 10 | 1 | 0 | 0 | 93% | |
| Jan 1, 2026 | 3 | 10 | 1 | 0 | 0 | 93% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 3, 2026
short_volume
Short Volume: VIR — 65.0% short (0.7M / 1.1M)
Short: 687,834 | Exempt: 94 | TRF Vol: 1,058,683 | Short Ratio: 65.0% | Off-exchange volume (dark pool + OTC)
May 29, 2026
short_volume
Short Volume: VIR — 56.7% short (0.6M / 1.1M)
Short: 603,778 | Exempt: 900 | TRF Vol: 1,065,769 | Short Ratio: 56.7% | Off-exchange volume (dark pool + OTC)
May 28, 2026
short_volume
Short Volume: VIR — 66.7% short (0.6M / 0.9M)
Short: 611,780 | Exempt: 3,300 | TRF Vol: 917,722 | Short Ratio: 66.7% | Off-exchange volume (dark pool + OTC)
May 23, 2026
Clinical Trial
Study of VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus Infection
Phase Phase 2 — COMPLETED
May 23, 2026
clinical_trial_readout
Results Pending: VIR-2218 (Phase 2) — Completed 68d ago
Trial: Study of VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus Infection
Sponsor: Vir Biotechnology, Inc.
Phase: Phase
May 19, 2026
short_volume
Short Volume: VIR — 68.6% short (0.4M / 0.6M)
Short: 413,944 | Exempt: 128 | TRF Vol: 603,146 | Short Ratio: 68.6% | Off-exchange volume (dark pool + OTC)
May 18, 2026
short_volume
Short Volume: VIR — 61.3% short (0.3M / 0.5M)
Short: 320,030 | Exempt: 3,921 | TRF Vol: 522,021 | Short Ratio: 61.3% | Off-exchange volume (dark pool + OTC)
May 15, 2026
short_volume
Short Volume: VIR — 56.6% short (0.3M / 0.6M)
Short: 318,111 | Exempt: 2,654 | TRF Vol: 561,827 | Short Ratio: 56.6% | Off-exchange volume (dark pool + OTC)
May 6, 2026
earnings_calendar
VIR Q1 2026 Earnings Scheduled — 2026-05-06
Apr 30, 2026
earnings_calendar
VIR Q1 2026 Earnings Scheduled — 2026-04-30
Apr 23, 2026
clinical_trial_readout
Results Pending: VIR-2218 (Phase 2) — Completed 38d ago
Trial: Study of VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus Infection
Sponsor: Vir Biotechnology, Inc.
Phase: Phase
Apr 16, 2026
Clinical Trial
Study of VIR-2218 With or Without Pegylated Interferon Alpha-2a for Treatment of Chronic Hepatitis B Virus Infection
Phase Phase 2 — COMPLETED
Apr 15, 2026
short_volume
Short Volume: VIR — 64.7% short (0.7M / 1.1M)
Short: 706,046 | Exempt: 0 | TRF Vol: 1,091,030 | Short Ratio: 64.7% | Off-exchange volume (dark pool + OTC)
Apr 14, 2026
short_volume
Short Volume: VIR — 59.2% short (0.6M / 1.0M)
Short: 612,607 | Exempt: 20,031 | TRF Vol: 1,035,610 | Short Ratio: 59.2% | Off-exchange volume (dark pool + OTC)
Apr 13, 2026
short_volume
Short Volume: VIR — 63.1% short (0.4M / 0.6M)
Short: 394,202 | Exempt: 30 | TRF Vol: 624,702 | Short Ratio: 63.1% | Off-exchange volume (dark pool + OTC)
Apr 9, 2026
short_volume
Short Volume: VIR — 56.5% short (0.5M / 0.8M)
Short: 472,024 | Exempt: 7,304 | TRF Vol: 835,922 | Short Ratio: 56.5% | Off-exchange volume (dark pool + OTC)
Apr 8, 2026
short_volume
Short Volume: VIR — 59.7% short (0.6M / 0.9M)
Short: 551,516 | Exempt: 710 | TRF Vol: 924,170 | Short Ratio: 59.7% | Off-exchange volume (dark pool + OTC)